<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03614403</url>
  </required_header>
  <id_info>
    <org_study_id>1397.271</org_study_id>
    <nct_id>NCT03614403</nct_id>
  </id_info>
  <brief_title>The Effect of Vitamin D3 on Postoperative Pain in Patients Undergoing Craniotomy</brief_title>
  <official_title>The Effect of Single High Dose of Vitamin D3 on Short-term Postoperative Pain in Patients Under Craniotomy for Brain Tumor Resection</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Shahid Beheshti University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Shahid Beheshti University</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Vitamin D is a hormone mainly synthesized in the skin in the presence of sunlight. Like other
      hormones, vitamin D plays a role in a wide range of processes in the body. Some studies have
      shown vitamin D has anti-inflammatory effects in the body by reducing the release of
      pro-inflammatory cytokines and suppressing T-cell responses. Therefore, vitamin D may be
      effective on reduce pain by such mechanisms. In this trial patients with brain tumor under
      craniotomy will receive a single high dose vitamin D compared to the control group.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A randomized, double blind, controlled trial will be conducted in intensive care unit (ICU)
      and neurosurgery ward, in Shohada-E-Tajrish hospital,Tehran, Iran. First, patients will be
      carefully checked for inclusion and exclusion criteria. Then, the eligible patients will
      complete the consent form for this study. 60 eligible brain tumor patients diagnosed by
      surgeon that are ready for craniotomy will be selected.These patients will be divided into
      two groups. Intervention group will be received an intramuscular (IM) single dose of vitamin
      D (300000 IU),while another group will not receive. Pain in patients will be checked daily by
      up to 3 days after surgery. Finally, the VAS pain score will be compared in both groups.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">July 30, 2017</start_date>
  <completion_date type="Actual">November 30, 2018</completion_date>
  <primary_completion_date type="Actual">November 30, 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Short-term postoperative pain: measured by the visual analogue scale or visual analog scale (VAS) that is a pain rating scale</measure>
    <time_frame>Up to three days after surgery</time_frame>
    <description>By questioning from patients for daily pain intensity based on the VAS scale in which pain intensity score by 0 to 10. The &quot;0&quot; and &quot;10&quot; score indicates &quot;no pain&quot; and &quot;worst pain&quot;,respectively. also &quot;1-3&quot; , &quot;4-6&quot; and &quot;7-9&quot; score indicates mild, mild to moderate and severe pain, respectively.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">60</enrollment>
  <condition>Brain Neoplasms</condition>
  <arm_group>
    <arm_group_label>Vitamin D</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Intervention patients will be received a single dose of 300000 IU vitamin D via intramuscular injection</description>
  </arm_group>
  <arm_group>
    <arm_group_label>control</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Control patients will not be received any intervention</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>vitamin D</intervention_name>
    <description>Fat-soluble vitamin D injection contain of 300,000 IU vitamin D that given via intramuscular injection</description>
    <arm_group_label>Vitamin D</arm_group_label>
    <other_name>Cholecalciferol</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Written informed consent of patient or legal representative

          -  25(OH)D level below 20ng/dL

        Exclusion Criteria:

          -  Other trial participation, including previous participation in the pilot trial

          -  Pregnant or lactating women

          -  Hypercalcemia

          -  Hyperphosphatemia

          -  Tuberculosis

          -  Sarcoidosis

          -  History of nephrolithiasis

          -  History of hyperparathyroidism

          -  Medications that interfere with vitamin D metabolism

          -  Renal Insufficiency
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Zahra Vahdat Shariatpanahi, MD, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Faculty of Nutrition and Food Technology,</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Faculty of Nutrition and Food Technology, Shahid Beheshti University of Medical Sciences</name>
      <address>
        <city>Tehran</city>
        <country>Iran, Islamic Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Iran, Islamic Republic of</country>
  </location_countries>
  <verification_date>April 2019</verification_date>
  <study_first_submitted>July 29, 2018</study_first_submitted>
  <study_first_submitted_qc>August 2, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">August 3, 2018</study_first_posted>
  <last_update_submitted>April 8, 2019</last_update_submitted>
  <last_update_submitted_qc>April 8, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">April 9, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Shahid Beheshti University</investigator_affiliation>
    <investigator_full_name>Zahra Vahdat Shariatpanahi</investigator_full_name>
    <investigator_title>Associate Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Brain Neoplasms</mesh_term>
    <mesh_term>Pain, Postoperative</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vitamin D</mesh_term>
    <mesh_term>Cholecalciferol</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

